Fundraising FoxOligomerix
4 known investors
Find your way into Oligomerix
Sign up to see every warm intro you have to Oligomerix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Oligomerix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Oligomerix is a biopharmaceutical company developing therapeutic compounds, with leadership focused on advancing drug candidates through clinical development stages.
Founders & leadership
Investors · 4
How we know: Counterview Capital's portfolio page · the VCSheet dataset · Not right? Tell us
Also in the syndicate · 3
Funding
SEC filings, press & company announcements$2.7M disclosed across 1 of 2 rounds · 2012–2022
- $2.7MSeries B ExtensionJun 2022 · 2 sourcesSource ↗
- Undisclosed amountSeries AApr 2012
Durand Venture Associates, LLC (lead), Wheatley MedTech Partners, L.P. (lead), Wheatley New York Partners LP (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Non-dilutive funding · 12 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $2.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $3.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $499.4K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $302.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2013 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2010 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2009 | $323.3K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2007 | $233.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Oligomerix do?
- Oligomerix is a biopharmaceutical company developing therapeutic compounds, with leadership focused on advancing drug candidates through clinical development stages.
- Who founded Oligomerix?
- Oligomerix was founded by James Moe, Eliot J. Davidowitz, Dr. Moe, Dr. Davidowitz.
- Who are Oligomerix's investors?
- Oligomerix's investors include Counterview Capital.
- How much funding has Oligomerix raised?
- Oligomerix has disclosed $2.7M raised across 1 of its 2 known rounds.